Olesen Bente, Frimodt-Møller Jakob, Leihof Rikke Fleron, Struve Carsten, Johnston Brian, Hansen Dennis S, Scheutz Flemming, Krogfelt Karen A, Kuskowski Michael A, Clabots Connie, Johnson James R
Department of Clinical Microbiology, Herlev Hospital, Herlev, Denmark
Department of Clinical Microbiology, Herlev Hospital, Herlev, Denmark Department of Microbiology and Infection Control, Statens Serum Institut, Copenhagen, Denmark.
Antimicrob Agents Chemother. 2014 Nov;58(11):6886-95. doi: 10.1128/AAC.03679-14. Epub 2014 Sep 8.
To identify possible explanations for the recent global emergence of Escherichia coli sequence type (ST) 131 (ST131), we analyzed temporal trends within ST131 O25 for antimicrobial resistance, virulence genes, biofilm formation, and the H30 and H30-Rx subclones. For this, we surveyed the WHO E. coli and Klebsiella Centre's E. coli collection (1957 to 2011) for ST131 isolates, characterized them extensively, and assessed them for temporal trends. Overall, antimicrobial resistance increased temporally in prevalence and extent, due mainly to the recent appearance of the H30 (1997) and H30-Rx (2005) ST131 subclones. In contrast, neither the total virulence gene content nor the prevalence of biofilm production increased temporally, although non-H30 isolates increasingly qualified as extraintestinal pathogenic E. coli (ExPEC). Whereas virotype D occurred from 1968 forward, virotypes A and C occurred only after 2000 and 2002, respectively, in association with the H30 and H30-Rx subclones, which were characterized by multidrug resistance (including extended-spectrum-beta-lactamase [ESBL] production: H30-Rx) and absence of biofilm production. Capsular antigen K100 occurred exclusively among H30-Rx isolates (55% prevalence). Pulsotypes corresponded broadly with subclones and virotypes. Thus, ST131 should be regarded not as a unitary entity but as a group of distinctive subclones, with its increasing antimicrobial resistance having a strong clonal basis, i.e., the emergence of the H30 and H30-Rx ST131 subclones, rather than representing acquisition of resistance by diverse ST131 strains. Distinctive characteristics of the H30-Rx subclone-including specific virulence genes (iutA, afa and dra, kpsII), the K100 capsule, multidrug resistance, and ESBL production-possibly contributed to epidemiologic success, and some (e.g., K100) might serve as vaccine targets.
为了找出近期全球范围内大肠杆菌序列类型(ST)131(ST131)出现的可能原因,我们分析了ST131 O25内抗菌药物耐药性、毒力基因、生物膜形成以及H30和H30-Rx亚克隆的时间趋势。为此,我们调查了世界卫生组织大肠杆菌和克雷伯菌中心的大肠杆菌菌株收集库(1957年至2011年)中的ST131分离株,对其进行了广泛的特征分析,并评估了它们的时间趋势。总体而言,抗菌药物耐药性在流行率和程度上随时间增加,这主要归因于近期出现的H30(1997年)和H30-Rx(2005年)ST131亚克隆。相比之下,尽管非H30分离株越来越符合肠外致病性大肠杆菌(ExPEC)的标准,但总的毒力基因含量和生物膜产生的流行率均未随时间增加。1968年以后出现了病毒型D,而病毒型A和C分别在2000年和2002年之后出现,与H30和H30-Rx亚克隆相关,这些亚克隆的特征是多重耐药(包括产超广谱β-内酰胺酶[ESBL]:H30-Rx)且不产生生物膜。荚膜抗原K100仅在H30-Rx分离株中出现(流行率为55%)。脉冲型与亚克隆和病毒型大致对应。因此,ST131不应被视为一个单一的实体,而应被视为一组独特的亚克隆,其抗菌药物耐药性的增加具有很强的克隆基础,即H30和H30-Rx ST131亚克隆的出现,而不是代表不同ST131菌株获得耐药性。H30-Rx亚克隆的独特特征——包括特定的毒力基因(iutA、afa和dra、kpsII)、K100荚膜、多重耐药和产ESBL——可能促成了其在流行病学上的成功,其中一些特征(如K100)可能成为疫苗靶点。